Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy

The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of B.U. ON. 2015-07, Vol.20 (4), p.994-1000
Hauptverfasser: Avci, Nilufer, Deligonul, Adem, Tolunay, Sahsine, Cubukcu, Erdem, Fatih Olmez, Omer, Altmisdortoglu, Ozgur, Tanriverdi, Ozgur, Aksoy, Asude, Kurt, Ender, Evrensel, Turkkan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1000
container_issue 4
container_start_page 994
container_title Journal of B.U. ON.
container_volume 20
creator Avci, Nilufer
Deligonul, Adem
Tolunay, Sahsine
Cubukcu, Erdem
Fatih Olmez, Omer
Altmisdortoglu, Ozgur
Tanriverdi, Ozgur
Aksoy, Asude
Kurt, Ender
Evrensel, Turkkan
description The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline-and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank-4.28, p
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1718074662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1718074662</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-5bb4f5f01ae1583571a4daaa1883655ea0297191b456e524b156c135217e9fe13</originalsourceid><addsrcrecordid>eNo1UE1rhDAUzKGlu2z3L5QcexHy1EQ9lqVfsNAe2rM89blm0SRNYov_vtKPuczADMMwF2wLIIpEqFRu2D6Es1ihBKiqvGKbVOWgRA5bNr96ezI2RN1yPTlsI7c9j_NkPR-XyQ22XX480-sxeowUVs0dRk0mBv6l48AbTxgib9G05PlsOvInq82JG7LYnedPNKs70GTjQB7dcs0uexwD7f94x94f7t8OT8nx5fH5cHdMXAoQE9k0eS97AUggy0wWgHmHiFCWmZKSUKRVARU0uVQk07wBqVrIZAoFVT1BtmO3v73O24-ZQqwnHVoaR1yXzaGGAkpR5Eqla_TmLzo3E3W183pCv9T_V2XfmgtnMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1718074662</pqid></control><display><type>article</type><title>Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Avci, Nilufer ; Deligonul, Adem ; Tolunay, Sahsine ; Cubukcu, Erdem ; Fatih Olmez, Omer ; Altmisdortoglu, Ozgur ; Tanriverdi, Ozgur ; Aksoy, Asude ; Kurt, Ender ; Evrensel, Turkkan</creator><creatorcontrib>Avci, Nilufer ; Deligonul, Adem ; Tolunay, Sahsine ; Cubukcu, Erdem ; Fatih Olmez, Omer ; Altmisdortoglu, Ozgur ; Tanriverdi, Ozgur ; Aksoy, Asude ; Kurt, Ender ; Evrensel, Turkkan</creatorcontrib><description>The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline-and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank-4.28, p&lt;0.05) and overall survival (OS) (log rank=3.96, p&lt;0.05), with high-grade TLI patients showing a better prognosis. Multivariate Cox regression analysis identified postoperative tumor size and low-grade TLI as the two main independent adverse prognostic factors. High-grade TLI may interfer with tumor growth and can represent a favorable prognostic factor in women with breast cancer undergoing NACT.</description><identifier>ISSN: 1107-0625</identifier><identifier>PMID: 26416041</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Breast Neoplasms - drug therapy ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Chemotherapy, Adjuvant ; Female ; Humans ; Lymphocytes, Tumor-Infiltrating - pathology ; Middle Aged ; Neoadjuvant Therapy ; Prognosis ; Prospective Studies</subject><ispartof>Journal of B.U. ON., 2015-07, Vol.20 (4), p.994-1000</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26416041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Avci, Nilufer</creatorcontrib><creatorcontrib>Deligonul, Adem</creatorcontrib><creatorcontrib>Tolunay, Sahsine</creatorcontrib><creatorcontrib>Cubukcu, Erdem</creatorcontrib><creatorcontrib>Fatih Olmez, Omer</creatorcontrib><creatorcontrib>Altmisdortoglu, Ozgur</creatorcontrib><creatorcontrib>Tanriverdi, Ozgur</creatorcontrib><creatorcontrib>Aksoy, Asude</creatorcontrib><creatorcontrib>Kurt, Ender</creatorcontrib><creatorcontrib>Evrensel, Turkkan</creatorcontrib><title>Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy</title><title>Journal of B.U. ON.</title><addtitle>J BUON</addtitle><description>The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline-and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank-4.28, p&lt;0.05) and overall survival (OS) (log rank=3.96, p&lt;0.05), with high-grade TLI patients showing a better prognosis. Multivariate Cox regression analysis identified postoperative tumor size and low-grade TLI as the two main independent adverse prognostic factors. High-grade TLI may interfer with tumor growth and can represent a favorable prognostic factor in women with breast cancer undergoing NACT.</description><subject>Adult</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Humans</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><issn>1107-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UE1rhDAUzKGlu2z3L5QcexHy1EQ9lqVfsNAe2rM89blm0SRNYov_vtKPuczADMMwF2wLIIpEqFRu2D6Es1ihBKiqvGKbVOWgRA5bNr96ezI2RN1yPTlsI7c9j_NkPR-XyQ22XX480-sxeowUVs0dRk0mBv6l48AbTxgib9G05PlsOvInq82JG7LYnedPNKs70GTjQB7dcs0uexwD7f94x94f7t8OT8nx5fH5cHdMXAoQE9k0eS97AUggy0wWgHmHiFCWmZKSUKRVARU0uVQk07wBqVrIZAoFVT1BtmO3v73O24-ZQqwnHVoaR1yXzaGGAkpR5Eqla_TmLzo3E3W183pCv9T_V2XfmgtnMg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Avci, Nilufer</creator><creator>Deligonul, Adem</creator><creator>Tolunay, Sahsine</creator><creator>Cubukcu, Erdem</creator><creator>Fatih Olmez, Omer</creator><creator>Altmisdortoglu, Ozgur</creator><creator>Tanriverdi, Ozgur</creator><creator>Aksoy, Asude</creator><creator>Kurt, Ender</creator><creator>Evrensel, Turkkan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy</title><author>Avci, Nilufer ; Deligonul, Adem ; Tolunay, Sahsine ; Cubukcu, Erdem ; Fatih Olmez, Omer ; Altmisdortoglu, Ozgur ; Tanriverdi, Ozgur ; Aksoy, Asude ; Kurt, Ender ; Evrensel, Turkkan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-5bb4f5f01ae1583571a4daaa1883655ea0297191b456e524b156c135217e9fe13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Humans</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><toplevel>online_resources</toplevel><creatorcontrib>Avci, Nilufer</creatorcontrib><creatorcontrib>Deligonul, Adem</creatorcontrib><creatorcontrib>Tolunay, Sahsine</creatorcontrib><creatorcontrib>Cubukcu, Erdem</creatorcontrib><creatorcontrib>Fatih Olmez, Omer</creatorcontrib><creatorcontrib>Altmisdortoglu, Ozgur</creatorcontrib><creatorcontrib>Tanriverdi, Ozgur</creatorcontrib><creatorcontrib>Aksoy, Asude</creatorcontrib><creatorcontrib>Kurt, Ender</creatorcontrib><creatorcontrib>Evrensel, Turkkan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of B.U. ON.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avci, Nilufer</au><au>Deligonul, Adem</au><au>Tolunay, Sahsine</au><au>Cubukcu, Erdem</au><au>Fatih Olmez, Omer</au><au>Altmisdortoglu, Ozgur</au><au>Tanriverdi, Ozgur</au><au>Aksoy, Asude</au><au>Kurt, Ender</au><au>Evrensel, Turkkan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy</atitle><jtitle>Journal of B.U. ON.</jtitle><addtitle>J BUON</addtitle><date>2015-07</date><risdate>2015</risdate><volume>20</volume><issue>4</issue><spage>994</spage><epage>1000</epage><pages>994-1000</pages><issn>1107-0625</issn><abstract>The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline-and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank-4.28, p&lt;0.05) and overall survival (OS) (log rank=3.96, p&lt;0.05), with high-grade TLI patients showing a better prognosis. Multivariate Cox regression analysis identified postoperative tumor size and low-grade TLI as the two main independent adverse prognostic factors. High-grade TLI may interfer with tumor growth and can represent a favorable prognostic factor in women with breast cancer undergoing NACT.</abstract><cop>Greece</cop><pmid>26416041</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1107-0625
ispartof Journal of B.U. ON., 2015-07, Vol.20 (4), p.994-1000
issn 1107-0625
language eng
recordid cdi_proquest_miscellaneous_1718074662
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Adult
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Chemotherapy, Adjuvant
Female
Humans
Lymphocytes, Tumor-Infiltrating - pathology
Middle Aged
Neoadjuvant Therapy
Prognosis
Prospective Studies
title Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T07%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20of%20tumor%20lymphocytic%20infiltrates%20in%20patients%20with%20breast%20cancer%20undergoing%20neoadjuvant%20chemotherapy&rft.jtitle=Journal%20of%20B.U.%20ON.&rft.au=Avci,%20Nilufer&rft.date=2015-07&rft.volume=20&rft.issue=4&rft.spage=994&rft.epage=1000&rft.pages=994-1000&rft.issn=1107-0625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1718074662%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1718074662&rft_id=info:pmid/26416041&rfr_iscdi=true